$PFE

Nifty, Sensex Fall for Seventh Straight Session as Oil Nears $100

Indian indices Nifty and Sensex fell for the seventh straight session as oil prices neared $100. Pfizer India hit a 52-week low after discontinuing Minipress XL, while Novartis India rose to a 52-week high following a strategic acquisition. Other notable movers included Tata Communications, Innovision, HMA Agro, Jupiter Wagons, Ceigall India, and Goldiam International, each reporting specific corporate developments.

Original reporting
Published Sep 8, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nifty, Sensex Fall for Seventh Straight Session as Oil Nears $100 — source image
Decision brief

The 30-second read

$PFEBearishLow
01

Why it matters

The market-wide decline reflects investor caution amid rising commodity costs; sector losers include pharma and banks, while select winners benefit from contract wins and acquisitions.

02

Market read

The article highlights a broad Indian market sell‑off with isolated corporate catalysts, indicating heightened volatility and sector rotation.

03

What to watch

The impact of oil price stability and potential policy support for Indian exporters could reverse the sell‑off.

Relevance 4/10Novelty 2/10Timing: Tuesday

Background

Nifty and Sensex slipped for a seventh consecutive session as oil prices approached $100, with mixed corporate news across Indian markets.

Company-level read

Ticker impact

$PFEBearishMedium confidence
Context

Pfizer discontinued marketing of Minipress XL in India, sending the stock down 6.22% to a 52‑week low.

Expected impact

Further downside risk if additional products are withdrawn.

Evidence & confidence

Market reacts to loss of a cardiovascular asset; limited upside without new pipeline news.

$NVSBullishMedium confidence
Context

Novartis India acquired Minipress trademarks for ₹1,250 cr, driving its stock up 11.12% to a 52‑week high.

Expected impact

Potential short‑term rally as investors price in revenue upside.

Evidence & confidence

Deal size is material for the Indian market; market already reflected a strong gain.

$IBNBullishLow confidence
Context

Biocon entered a partnership for Pertuzumab supply in Brazil, expanding its oncology footprint.

Expected impact

Potential incremental upside if partnership scales.

Evidence & confidence

Impact limited by early‑stage partnership stage.

Market effects

Broad weakness across Indian equities, especially financials and pharma, with isolated gains in select stocks.

Indian market sell‑off may pressure regional ETFs and increase demand for safe‑haven assets.

Oil nearing $100 and Indian index declines add to global risk‑off sentiment.

Counterpoint

Despite overall market weakness, several stocks hit 52‑week highs, suggesting sector‑specific buying opportunities.

Key entities

  • Pfizer

    Discontinued Minipress XL in India, causing stock drop.

  • Novartis India

    Acquired Minipress trademarks, driving share rally.

  • Tata Communications

    Dissolved Kaleyra Africa subsidiary.

  • Tata Consultancy Services

    Won Odisha government contract for OSWAS 3.0.

  • Biocon

    Partnered for Pertuzumab supply in Brazil.

Related articles

$PFEMedAI 8/10

PFE Looks 4.4% Overvalued on GF Value™ Amid Strong Dividend Fund

Pfizer (PFE) and BioNTech received Health Canada authorization for their updated COVID-19 vaccine targeting the Omicron XFG variant. The company offers a 6.21% dividend yield with a 56% payout ratio and a 2.4% 3-year dividend growth rate. Pfizer's GF Value™ is $26.46, slightly below its market price of $27.64, indicating a 4.4% overvaluation. The company's GF Score™ is 75/100, reflecting strong profitability and momentum but moderate growth and financial strength.

$NVSMedAI 8/10

Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

Novartis (NVS) and Ionis (IONS) reported that their experimental cholesterol drug, pelacarsen, failed to reduce heart attacks and strokes in a late-stage trial, despite lowering Lp(a) levels. Shares of both companies fell in aftermarket trading. Novartis and Ionis acknowledged the setback but highlighted other pipeline opportunities. The failure removes a potential growth driver for both companies, with Novartis facing greater pressure to replace revenue as older drugs face patent challenges.